A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection.
Daily dose buprenorphine was approved by the Food and Drug Administration (FDA) in 2002 and has proven to be effective in the treatment of opioid use disorders (OUD). However, daily doses require patients to recommit to taking medication every day and can result in cravings near the end of the 24-hour cycle. Although the National Institute on Drug Abuse (NIDA) did not fund this current study, it did support the development of buprenorphine as a treatment for OUD. NIDA’s support also contributed to the development and approval of another long-acting buprenorphine formulation — a six-month subcutaneous implant for some patients who have stabilized on daily dosing (Probuphine®).
Full story at drugabuse.org
Due to the age of the material, the following courses will be removed from the Quantum library on 3/01/2019. After this date you will be unable to take these courses for CE Credit.
Use our discount code of CEUs4You and receive 10% off our discontinuing courses.
1. Viral Hepatitis in People with Substance Use Disorders
2. Medicaid Coverage of Medications to Treat Alcohol and Opioid Use Disorders
3. Diabetes Care for Clients in Behavioral Health Treatment
Quantum Units Education
CE Support Staff
The National Institute on Drug Abuse (NIDA) today announced the availability of informational resources for clinicians interested in initiating buprenorphine treatment in emergency department settings. Buprenorphine is one of several medicines available for use in many emergency departments to treat opioid use disorders (OUD). The materials were developed by emergency department specialists at Yale University with grant support from NIDA, and contract support from NIDA’s Clinical Trials Network. NIDA is part of the National Institutes of Health.
Emergency department clinicians face unique challenges when faced with patients suffering from opioid overdoses or other effects of OUD. They can often reverse overdoses using the medication naloxone, however, that medication alone does not constitute treatment for the addiction itself. This makes the emergency setting an ideal place for clinicians to begin treatment conversations with patients, however, there have been few tools available to guide them. Since 2002, emergency clinicians have been able to administer buprenorphine to help patients manage opioid withdrawal symptoms, but the practice is still new in many emergency department settings.
Full story at drugabuse.org
A state-led initiative created within the Rhode Island correctional system showed that offering medication to inmates with opioid use disorders reduced fatal overdoses once the inmates were released. The reduction in fatal overdoses was large enough to have a significant effect on the death rate from opioid overdoses statewide. The research was funded by the National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, as well as the Centers for Disease Control and Prevention.
Every person entering the Rhode Island correctional system was screened for opioid addiction and those who needed it were provided with evidence-based medication assisted treatment (MAT), which included the drugs methadone, buprenorphine, or naltrexone. In addition, a system of 12 community-based Centers of Excellence in MAT were established to continue MAT therapy and provide support after their release from prison or jail.
Full story at drugabuse.gov